10,357 Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP bought a new position in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 10,357 shares of the company’s stock, valued at approximately $246,000.

A number of other institutional investors have also recently bought and sold shares of the stock. RA Capital Management L.P. acquired a new stake in shares of LENZ Therapeutics during the first quarter worth $93,313,000. Vanguard Group Inc. bought a new stake in shares of LENZ Therapeutics in the first quarter valued at about $4,621,000. Ikarian Capital LLC acquired a new position in shares of LENZ Therapeutics during the first quarter worth about $1,898,000. Wealth Enhancement Advisory Services LLC bought a new position in shares of LENZ Therapeutics during the second quarter worth about $1,437,000. Finally, Renaissance Technologies LLC raised its position in LENZ Therapeutics by 28.4% in the 2nd quarter. Renaissance Technologies LLC now owns 60,166 shares of the company’s stock valued at $1,040,000 after buying an additional 13,300 shares during the last quarter. Institutional investors own 54.32% of the company’s stock.

LENZ Therapeutics Stock Performance

Shares of LENZ opened at $35.50 on Friday. The company’s fifty day simple moving average is $27.29 and its 200 day simple moving average is $22.54. LENZ Therapeutics, Inc. has a 1-year low of $14.42 and a 1-year high of $38.93.

LENZ Therapeutics (NASDAQ:LENZ) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.09. During the same quarter last year, the business earned ($1.33) EPS. Equities analysts forecast that LENZ Therapeutics, Inc. will post -2.09 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. William Blair raised shares of LENZ Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Piper Sandler reaffirmed an “overweight” rating and issued a $36.00 target price on shares of LENZ Therapeutics in a research report on Thursday, August 15th. HC Wainwright reissued a “buy” rating and set a $38.00 price target on shares of LENZ Therapeutics in a research report on Thursday, November 7th. Finally, Raymond James began coverage on shares of LENZ Therapeutics in a research note on Friday, September 27th. They set an “outperform” rating and a $37.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $35.40.

LENZ Therapeutics Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.